J Neurocrit Care.  2018 Dec;11(2):81-85. 10.18700/jnc.180067.

Glucose Control in Intensive Care Unit Patients: Recent Updates

• Rhee SY

• KMID: 2434833
• DOI: http://doi.org/10.18700/jnc.180067

Abstract

Proper glucose management in hospitalized patients can improve clinical outcomes. In particular, intensive care unit (ICU) patients are known to have significantly higher rates of mortality from changes in blood glucose due to severe comorbidities. Improving glucose control in ICU patients, therefore, can improve mortality and prognosis. Several studies related to the management of blood glucose in the ICU patients have been conducted. Intensive glucose management of surgical ICU patients has been successful. However, studies on medical ICU patients did not demonstrate positive effects of strict glycemic control. There is no independent glucose management goal for neurological ICU patients. However, maintenance of the usual glucose control target of 140-180 mg/dL is recommended for ICU patients. Intravenous insulin infusion is essential for glucose control in ICU patients not consuming a regular diet, and caution should be exercised to prevent hypoglycemia.

Keyword

Glucose; Intensive care units; Critical care; Disease management

MeSH Terms

Blood Glucose
Comorbidity
Critical Care*
Diet
Disease Management
Glucose*
Humans
Hypoglycemia
Insulin
Intensive Care Units*
Mortality
Prognosis
Blood Glucose
Glucose
Insulin

Reference

1. Lee KW. Costs of diabetes mellitus in Korea. Diabetes Metab J. 2011; 35:567–70.

2. Ustulin M, Woo J, Woo JT, Rhee SY. Characteristics of frequent emergency department users with type 2 diabetes mellitus in Korea. J Diabetes Investig. 2018; 9:430–7.

3. Kim TH, Chun KH, Kim HJ, Han SJ, Kim DJ, Kwak J, et al. Direct medical costs for patients with type 2 diabetes and related complications: a prospective cohort study based on the Korean National Diabetes Program. J Korean Med Sci. 2012; 27:876–82.

4. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006; 355:1903–11.

5. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc. 2003; 78:1471–8.

6. Trence DL, Kelly JL, Hirsch IB. The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change. J Clin Endocrinol Metab. 2003; 88:2430–7.

7. Metchick LN, Petit WA Jr, Inzucchi SE. Inpatient management of diabetes mellitus. Am J Med. 2002; 113:317–23.

8. Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD, et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J. 2006; 27:1289–97.

9. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of inhospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002; 87:978–82.

10. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999; 67:352–60. discussion 360-2.

11. Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003; 125:1007–21.

12. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995; 26:57–65.

13. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001; 345:1359–67.

14. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006; 354:449–61.

15. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360:1283–97.

16. Gray CS, Hildreth AJ, Sandercock PA, O’Connell JE, Johnston DE, Cartlidge NE, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007; 6:397–406.

17. Kramer AH, Roberts DJ, Zygun DA. Optimal glycemic control in neurocritical care patients: a systematic review and meta-analysis. Crit Care. 2012; 16:R203.

18. NICE-SUGAR Study Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group and the Canadian Critical Care Trials Group, Finfer S, Chittock D, Li Y, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study. Intensive Care Med. 2015; 41:1037–47.

19. Kramer AH, Zygun DA. Neurocritical care: why does it make a difference? Curr Opin Crit Care. 2014; 20:174–81.

20. Bruno A, Durkalski VL, Hall CE, Juneja R, Barsan WG, Janis S, et al. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. Int J Stroke. 2014; 9:246–51.

21. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33:2569–619.

22. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009; 32:1119–31.

23. Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2011; 154:260–7.

24. Jacobi J, Bircher N, Krinsley J, Agus M, Braithwaite SS, Deutschman C, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med. 2012; 40:3251–76.

25. George S, Dale J, Stanisstreet D; Joint British Diabetes Societies (JBDS) for Inpatient Care, JBDS Medical VRIII Writing Group. A guideline for the use of variable rate intravenous insulin infusion in medical inpatients. Diabet Med. 2015; 32:706–13.

26. Korean Diabetes Association. Treatment Guideline for Diabetes. Seoul: Goldgihoek;2015.

27. American Diabetes Association. 14. diabetes care in the hospital: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41(Suppl 1):S144–51.

28. Goldberg PA, Siegel MD, Sherwin RS, Halickman JI, Lee M, Bailey VA, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care. 2004; 27:461–7.

29. Markovitz LJ, Wiechmann RJ, Harris N, Hayden V, Cooper J, Johnson G, et al. Description and evaluation of a glycemic management protocol for patients with diabetes undergoing heart surgery. Endocr Pract. 2002; 8:10–8.

30. DeSantis AJ, Schmeltz LR, Schmidt K, O’Shea-Mahler E, Rhee C, Wells A, et al. Inpatient management of hyperglycemia: the Northwestern experience. Endocr Pract. 2006; 12:491–505.

31. American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010; 33 Suppl 1:S11–61.

32. Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007; 30:2181–6.

33. Ko SH, Hur KY, Rhee SY, Kim NH, Moon MK, Park SO, et al. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Diabetes Metab J. 2017; 41:337–48.

34. Krinsley JS, Chase JG, Gunst J, Martensson J, Schultz MJ, Taccone FS, et al. Continuous glucose monitoring in the ICU: clinical considerations and consensus. Crit Care. 2017; 21:197.

35. Rhee SY, Han SW, Woo JT. Artificial pancreas: a concise review. J Korean Diabetes. 2017; 18:141–9.